{"id":5028,"date":"2026-11-17T00:23:46","date_gmt":"2026-11-17T05:23:46","guid":{"rendered":"https:\/\/mivado.com\/mgp\/?p=5028"},"modified":"2026-11-17T00:23:46","modified_gmt":"2026-11-17T05:23:46","slug":"innovation-in-pharmaceutical-risk-assessment","status":"publish","type":"post","link":"https:\/\/mivado.com\/mgp\/innovation-in-pharmaceutical-risk-assessment\/","title":{"rendered":"Innovation in Pharmaceutical Risk Assessment"},"content":{"rendered":"<div class=\"wpb-content-wrapper\" id=\"wpb-content-root\"><p>[vc_row][vc_column][vc_column_text]<\/p>\n<h1><span lang=\"EN-US\">Innovation in Pharmaceutical Risk Assessment: Using FMEA to Identify Critical Material Attributes (CMAs).<\/span><\/h1>\n<h3><span lang=\"EN-US\"> A Step-by-Step Walkthrough: <\/span>Learn how to apply FMEA in pharmaceutical development to identify CMAs, with a worked example of wet granulation before and after DoE.<\/h3>\n<p>How to Use FMEA to Identify Critical Material Attributes (CMAs)?\u00a0 Why Is FMEA Still the Most Practical Innovation in Pharmaceutical Risk Assessment?<\/p>\n<p>In Quality by Design (QbD), the real innovation isn&#8217;t a new tool; it is using an established tool at the right moments with the right data. Failure Mode and Effects Analysis (FMEA) is exactly that. Originally standardised for engineering use (<a href=\"https:\/\/webstore.iec.ch\/en\/publication\/26359\" target=\"_blank\" rel=\"noopener\">IEC 60812:2018<\/a>), FMEA is cited in <a href=\"extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q9%28R1%29_Guideline_Step4_2025_0115_0.pdf\" target=\"_blank\" rel=\"noopener\">ICH Q9<\/a> as <span style=\"box-sizing: border-box; margin: 0px; padding: 0px;\">a recognised\u00a0<a target=\"_blank\" rel=\"noopener\">quality risk management<\/a> tool<\/span>, and it fits neatly into the product development logic of <a href=\"extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/database.ich.org\/sites\/default\/files\/Q8%28R2%29%20Guideline.pdf\" target=\"_blank\" rel=\"noopener\">ICH Q8(R2)<\/a> and <a href=\"extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/database.ich.org\/sites\/default\/files\/Q11%20Guideline.pdf\" target=\"_blank\" rel=\"noopener\">ICH Q11<\/a> [1\u20134].<\/p>\n<p>The most effective teams do not run FMEA once and file it. They run it twice:<\/p>\n<p>1. Before experimentation, to screen many material attributes and decide which deserves a Design of Experiments (DoE).<br \/>\n2. After experimentation, to confirm that the control strategy has genuinely reduced risk to an acceptable level.<\/p>\n<p>This article walks through both passes using a worked wet granulation example, so you can apply the method straight away to your own CMA identification exercise.[\/vc_column_text][vc_column_text]<\/p>\n<h2>Key Definitions (Quick Refresher)<\/h2>\n<p>\u2022 CQA (Critical Quality Attribute): a physical, chemical, biological or microbiological property that should be within an appropriate limit to ensure the desired product quality [1].<br \/>\n\u2022 CMA (Critical Material Attribute): a property of an input material (API or excipient) whose variability has a meaningful impact on a CQA. CMAs are commonly discussed together with Critical Process Parameters (CPPs) in the QbD literature [1, 5].<br \/>\n\u2022 FMEA: a structured method that scores each failure mode on Severity (S), Occurrence (O) and Detectability (D). The product of the three gives the Risk Priority Number (RPN) [3, 6].<\/p>\n<h2>The Worked Example: A High-Shear Wet Granulation Process<\/h2>\n<p>Scenario (illustrative, not a real product): an immediate-release tablet containing a poorly soluble, low-dose API, manufactured by high-shear wet granulation, fluid-bed drying, milling, lubrication and compression.<\/p>\n<p><strong>Target CQAs<\/strong>: dissolution, content uniformity, assay and degradation products, tablet hardness and friability.<\/p>\n<p>All scores and results below are hypothetical and are provided to teach the method. Always base your own ratings on prior knowledge, literature, supplier data, and experimentation [2, 3].[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]<\/p>\n<h2>Step 1: Define the Scope and the Scoring Scales<\/h2>\n<p>Before scoring anything, agree on the following as a cross-functional team (formulation, analytical, manufacturing, QA, regulatory):<\/p>\n<p>\u2022 Scope: material attributes of the API and excipients only (process parameters are assessed in a separate or parallel FMEA).<br \/>\n\u2022 Scales: 1\u201310 for each of S, O and D, with written anchor definitions. For example, Severity 9\u201310 means a direct impact on patient safety or efficacy; Detectability 10 means the failure cannot be detected before release.<br \/>\n\u2022 Action thresholds: for example, RPN above 100, or any Severity of 8 or higher regardless of RPN, triggers further study.<\/p>\n<p>The second threshold matters. A high-severity item with a low occurrence can produce a deceptively small RPN, so a severity override is good practice. ICH Q9(R1) also stresses managing subjectivity in risk scoring, which is why documented scale definitions and a facilitated team session are essential [2].[\/vc_column_text][vc_column_text]<\/p>\n<h2>Step 2: List Material Attributes and Failure Modes<\/h2>\n<p>Using a process map and the Quality Target Product Profile (QTPP), list each input material and its potentially variable attributes. For each, describe the failure mode (what could go wrong) and its effect on the CQAs.<\/p>\n<h2>Step 3: First FMEA Pass \u2013 Screening Potential CMAs<\/h2>\n<p>At this stage, the team relies on prior knowledge, supplier information, and literature. Detectability reflects current controls (for example, supplier certificate of analysis only).[\/vc_column_text][vc_single_image][vc_column_text]<strong>Result of pass one:<\/strong> from seven candidates, five are carried forward as potential CMAs. Notice that no attribute is called &#8220;critical&#8221; yet. Criticality is confirmed with data, not with opinion [1, 5].[\/vc_column_text][vc_column_text]<\/p>\n<h2>Step 4: Use the FMEA Output to Design the DoE<\/h2>\n<p>The FMEA tells you what to put in the experimental design. A practical approach:<\/p>\n<p>1. Choose a screening design (for example, a fractional factorial) that includes the five flagged attributes plus the two or three highest-risk process parameters, such as binder liquid amount and wet massing time.<\/p>\n<p>2. Define responses linked to the CQAs: dissolution at a discriminating time point, content uniformity, granule size distribution, hardness.<\/p>\n<p>3. Analyse main effects and interactions, and judge significance against the analytical and process variability.<\/p>\n<p>This links the risk assessment directly to the design space and knowledge-generation approach described in ICH Q8(R2) [1].<\/p>\n<h3>Hypothetical DoE conclusions:<\/h3>\n<p>\u2022 API D90 and binder viscosity grade significantly affect dissolution ? confirmed CMAs.<\/p>\n<p>\u2022 Mg stearate surface area interacts with lubrication time on hardness and dissolution ? confirmed CMA, controlled together with the lubrication CPP.<\/p>\n<p>\u2022 MCC moisture significantly affects granule size ? confirmed CMA, controlled via a loss-on-drying limit.<\/p>\n<p>\u2022 API polymorph showed no change within the tested range, but severity remains high ? retained as a controlled attribute by specification.[\/vc_column_text][vc_column_text]<\/p>\n<h2>Step 5: Define the Control Strategy<\/h2>\n<p>Translate the findings into actions, in line with ICH Q10 and Q11 expectations for a lifecycle control strategy [4, 7]:<br \/>\n\u2022 API D90: specification NMT 40 \u00b5m (illustrative) with supplier agreement and incoming testing.<br \/>\n\u2022 Binder: defined viscosity range in the material specification.<br \/>\n\u2022 MCC: incoming loss-on-drying limit and an in-process moisture check.<br \/>\n\u2022 Mg stearate: specific surface area range and a fixed lubrication time.<br \/>\n\u2022 API polymorph: confirmed on each API batch or on a justified periodic basis.<\/p>\n<h2>Step 6: Second FMEA Pass \u2013 Verifying Risk Reduction<\/h2>\n<p>Now repeat the FMEA using the experimental knowledge and the new controls. Here is a key principle: Severity usually does not change, because the consequence of a failure is inherent to the product. Risk is reduced by lowering Occurrence (better control, tighter specifications) and Detectability (better testing).[\/vc_column_text][vc_single_image][vc_column_text]All residual RPNs fall below the 100 threshold, and the high-severity items have a low combined O \u00d7 D. The team documents the rationale, records the confirmed CMAs, and feeds them into the process validation strategy and ongoing monitoring [8].<\/p>\n<h3>Common Pitfalls to Avoid<\/h3>\n<p>\u2022 Treating RPN as absolute truth. RPN is a ranking aid, not a measurement. Use severity overrides and scientific justification [2, 6].<br \/>\n\u2022 Scoring without data. Every score needs a documented rationale (literature, experience, experiment).<br \/>\n\u2022 Running FMEA only once. Without the second pass, there is no evidence that the control strategy worked.<br \/>\n\u2022 Mixing material and process risks in one table. Keep CMAs and CPPs distinct, then link them through interactions.<br \/>\n\u2022 Forgetting the lifecycle. Revisit the FMEA when suppliers, scale, or site change, as expected under ICH Q9(R1) and Q10 [2, 7].<\/p>\n<h3>Key Takeaways<\/h3>\n<p>1. FMEA is a practical, regulator-recognised way to screen and confirm CMAs.<br \/>\n2. Use it twice: first to focus your DoE, then to demonstrate residual risk reduction.<br \/>\n3. Reduce risk through Occurrence and Detectability, not by rescoring Severity.<br \/>\n4. Document scales, rationale, and decisions to keep the assessment defensible and reproducible.[\/vc_column_text][vc_cta h2=&#8221;Take the Next Step&#8221; el_width=&#8221;100&#8243; btn_position=&#8221;bottom&#8221; btn_title=&#8221;Tell us about your next FMEA Activity&#8221; btn_custom_text=&#8221;#FFFFFF&#8221; btn_custom_background=&#8221;#1E73BE&#8221; btn_i_icon_fontawesome=&#8221;fa fa-solid fa-satellite-dish&#8221; btn_css_animation=&#8221;none&#8221; add_button=&#8221;true&#8221; btn_link=&#8221;url:https%3A%2F%2Fmivado.com%2Feshop%2Fappointement-page%2F&#8221; btn_add_icon=&#8221;true&#8221; btn_custom_hover_text=&#8221;#000000&#8243; btn_custom_hover_background=&#8221;#152F46&#8243;]Ready to make your FMEA and CMA identification more consistent, traceable, and audit-ready?<\/p>\n<p>Visit\u00a0 <a href=\"https:\/\/mivado.com\/mgp\/\"><strong>Mivado GlobalPerformance<\/strong><\/a>\u00a0to discover how Mivado can support your pharmaceutical risk assessment and QbD activities, and get in touch to discuss your project.[\/vc_cta][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Innovation in Pharmaceutical Risk Assessment: Using FMEA to Identify Critical Material Attributes (CMAs). A Step-by-Step Walkthrough: Learn how to apply FMEA in pharmaceutical development to identify CMAs, with a worked example of wet granulation before and after DoE.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[4],"tags":[],"class_list":["post-5028","post","type-post","status-publish","format-standard","hentry","category-general"],"jetpack_publicize_connections":[],"wps_subtitle":"Using FMEA to Identify Critical Material Attributes (CMAs)","jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/mivado.com\/mgp\/wp-json\/wp\/v2\/posts\/5028","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mivado.com\/mgp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mivado.com\/mgp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mivado.com\/mgp\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mivado.com\/mgp\/wp-json\/wp\/v2\/comments?post=5028"}],"version-history":[{"count":10,"href":"https:\/\/mivado.com\/mgp\/wp-json\/wp\/v2\/posts\/5028\/revisions"}],"predecessor-version":[{"id":5045,"href":"https:\/\/mivado.com\/mgp\/wp-json\/wp\/v2\/posts\/5028\/revisions\/5045"}],"wp:attachment":[{"href":"https:\/\/mivado.com\/mgp\/wp-json\/wp\/v2\/media?parent=5028"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mivado.com\/mgp\/wp-json\/wp\/v2\/categories?post=5028"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mivado.com\/mgp\/wp-json\/wp\/v2\/tags?post=5028"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}